The phase 2 CAVALLI (NCT02055820) study assessed efficacy and safety of venetoclax, a
selective B-cell lymphoma-2 (Bcl-2) inhibitor, with rituximab plus cyclophosphamide, …

Maternally inherited diabetes with deafness is rare diabetes caused by a mitochondrial DNA
defect. 85% of cases are associated with m.3243A > G mutation. It is important to diagnose …

… The first draft of the manuscript was written by Farheen Mir. Editorial support under the
direction of Farheen Mir was provided by Louise Profit of Gardiner-Caldwell Communications, …

A minority of patients with follicular lymphoma (FL) undergo histological transformation (HT).
This retrospective analysis of 549 patients from the phase 3 GALLIUM study (NCT01332968…

Conflict of interest: COI declared-see note COI notes: Conflict of interest statement CRB is
an employee at Genentech, Inc. and has equity ownership in Roche. FM is an employee of …

Introduction: BCL2 overexpression leading to evasion of apoptosis is common in
hematologic malignancies. In DLBCL, 50% of patients (pts) overexpress BCL2 protein, 30% …

Single-nucleotide polymorphisms (SNPs) have been shown to influence Fcγ receptor (FcγR)
affinity and activity, but their effect on treatment response is unclear. We assessed their …

Background Although advanced‑stage follicular lymphoma (FL) is considered incurable,
survival has improved with the introduction of the anti-CD20 antibodies, rituximab (R) and …

Fc γ receptor IIB (FcγRIIB) is an inhibitory molecule capable of reducing antibody
immunotherapy efficacy. We hypothesized its expression could confer resistance in patients with …

Complete metabolic response (CMR) on PET/CT was the sole independent predictor of
overall survival in the PET substudy of the phase III GALLIUM trial ( NCT01332968 ) in first-line …